Topic Code HORIZON-HLTH-2026-01-DISEASE-15 F&T Portal
Call Identifier HORIZON-HLTH-2026-01 Call 01 — single stage (2026)
Instrument HORIZON-CSA Coordination and Support Action
Budget Model Lump Sum HORIZON-AG-LS
Funding Rate 100% Annex G — CSA = 100%
Page Limit (Part B) 28 pages CSA + lump sum (Annex A)
Evaluation Thresholds 4 / 4 / 4 · cum. 12 Non-standard — topic override
Expected Projects 1 ~€1.9M per project (WP stated)
Destination Tackling diseases and reducing disease burden WP Part 4
Cluster / Pillar Cluster 1 / Pillar II Health
China Eligibility Eligible ✓ CSA not restricted (RIA/IA only)
Special Conditions Coordinator: EU/AC only Coordinator must be from MS or AC
Verify: Open this topic on the F&T Portal →  ·  Sources: General Annexes 2026-2027, WP Part 4
See what a full Decision Brief looks like →
Compliance traps · Scoring playbook · Consortium blueprint · 2 free examples available
China is eligible for this topic. The destination’s China restriction applies to RIA and IA only — CSA is not restricted.
This topic uses non-standard evaluation thresholds: 4 (Excellence) / 4 (Impact) / 4 (Implementation), cumulative 12. Standard thresholds are 3/3/3 cumulative 10.
US entities eligible: In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, legal entities established in the United States of America are eligible to receive Union funding under this topic.
Copernicus/Galileo: If the project uses satellite-based earth observation, positioning, navigation and/or related timing data, beneficiaries must make use of Copernicus and/or Galileo/EGNOS.

Expected Outcomes

  1. Healthcare providers, policymakers and researchers benefit from an improved knowledge base and collaboration on the key challenges and gaps on cardiovascular health research and a conceptual framework to develop a roadmap for research and innovation is established.
  2. Health systems gain improved and standardised evidence to better prevent, diagnose or treat cardiovascular diseases (CVDs) and associated comorbidities, based on the research results on prediction, early detection, screening practices and diagnostic methods and tools, including via personalised and digital approaches.
  3. Medical and non-medical health professionals and technology developers have an increased knowledge, awareness and capacity to uptake and deliver effective and innovative approaches for risk prediction, early detection, screening and health management strategies, such as Virtual Human Twins (VHT) or Artificial Intelligence (AI)-based applications. This involves supporting, strategic foresight, improving health literacy and cross-sectoral knowledge exchange and collaboration to drive innovation in personalised prevention and cardiovascular risk prediction.
  4. Healthcare providers and policymakers have an improved knowledge base to inform future strategies for early detection and prevention of CVDs, with specific attention to women and vulnerable groups, through research on personalised risk prediction approaches that consider multiple and interacting risk factors (e.g. genetic predisposition, environmental pollutants, diet, lifestyle habits, multimorbidity, sex and gender).

Want the full analysis?

The key facts above tell you WHAT. The full Decision Brief tells you HOW to win.

Compliance traps Scoring playbook Consortium blueprint Positioning guide Red flags Quick-start checklist
Order Full Brief — €79
Delivered within 1 working day
Disclaimer: This page is produced using advanced AI analysis and reviewed by an experienced EU grant engineer. While we take care to ensure accuracy, the information may contain errors or become outdated. It is the applicant’s sole responsibility to verify all facts against the official EU Funding & Tenders Portal before making any decisions. Global Disruption accepts no liability for errors, omissions, or decisions made based on this content. No refunds are offered for Key Facts pages or Decision Briefs.